General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly. The Zacks Consensus Estimate for sales and earnings is pegged at $502.8 million ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated ... the Center for Cancer Research at the National Cancer Institute, ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...